Acute Kidney Injury (AKI) Epidemiology Forecast Report, 2032: Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan – ResearchAndMarkets.com

Acute Kidney Injury (AKI) Epidemiology Forecast Report, 2032: Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan – ResearchAndMarkets.com




Acute Kidney Injury (AKI) Epidemiology Forecast Report, 2032: Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Acute Kidney Injury (AKI) – Epidemiology Forecast – 2032” report has been added to ResearchAndMarkets.com’s offering.

This Acute Kidney Injury – Epidemiology Forecast- 2032″ report delivers an in-depth understanding of the AKI, historical and forecasted epidemiology trends in the United States, the EU-5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Population of AKI in Hospitalized Patients, Mortality Adjusted Incident Population of AKI in Hospitalized Patients, Stage-specific Incident Population of AKI and, Age-specific Incident Population of AKI in the 7MM market covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise Acute Kidney Injury Epidemiology

  • The epidemiology segment also provides the AKI epidemiology data and findings across the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The total Mortality-adjusted Incident Cases of AKI in the 7MM comprised of 6,470,038 cases in 2021 and are projected to increase during the forecast period.
  • The total Mortality-adjusted Incident Cases of AKI in the United States is 2,210,647 in 2021.
  • The US contributed to the largest incident population of AKI, accounting for ~ 34% of the 7MM in 2021.
  • Among the EU-5 countries, Germany accounted for the highest number of AKI cases, followed by France, whereas Spain accounted for the lowest cases in 2021.
  • In Japan, the total mortality-adjusted Incident Cases of AKI was 1,272,824 in 2021 and is anticipated to rise during the forecast period.
  • The stage-specific cases of AKI includes stage I, Stage II and, stage III. Out of which maximum cases were reported in stage I AKI followed by stage II and Stage III.

Scope of the Report

  • The report covers the descriptive overview of AKI, explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the AKI epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for AKI are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of AKI market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM AKI market.

Report Highlights

  • In the coming years, AKI market is set to change due emerging therapies in the pipeline, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence AKI R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • As per the analysis the subtypes- specific of AKI include Stage I, Stage II and Stage III.

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of AKI?
  • What is the historical AKI patient pool in the United States, the EU-5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of AKI at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to AKI?
  • Out of the above-mentioned countries, which country would have the highest incident population of AKI during the study period (2019-2032)?
  • At what CAGR the population is expected to grow across the 7MM during the study period (2019-2032)?

Reasons to Buy

  • The report will help in developing business strategies by understanding trends shaping and driving the AKI.
  • To understand the future market competition in the AKI market and Insightful review of the SWOT analysis of AKI.
  • Organize sales and marketing efforts by identifying the best opportunities for AKI in the US, EU-5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • The AKI Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources.

AKI Report Insights

  • Patient Population
  • Therapeutic Approaches
  • 7MM Coverage
  • AKI Epidemiology Segmentation

     

     

Key Topics Covered:

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Epidemiology And Methodology

5. Disease Background And Overview

5.1. Introduction

5.2. Symptoms

5.3. Types Of Acute Kidney Injury

5.4. Stages Classification

5.5. Risk Factors

5.6. Etiology

6. Epidemiology And Patient Population

6.1. Key Findings

6.2. Assumptions And Rationale

6.2.1. United States

6.2.2. Eu-5

6.2.3. Japan

6.3. Total Incidence Of Acute Kidney Injury (AKI) In Hospitalized Patients In The 7mm

6.4. Total Mortality Adjusted Incident Population Of AKI In Hospitalized Patients In The 7mm

6.5. The United States

6.6. Eu-5

6.7. Japan

7. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/v2bb3s

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900